CLINE CHRISTOPHER R. (CHIEF FINANCIAL OFFICER) sold 6.6% of their position (8.33K shares) of TRAVERE THERAPEUTICS, INC. on the open market
Open‑market sale worth $349.0K — a moderate reduction. Review remaining holdings and any 10b5‑1 plan disclosures.
S · 4 sales
Filed: 4/16/2026ACC: 0001943192-26-000003
Officer· CHIEF FINANCIAL OFFICER
Since Feb 2026
+5.67K
Net shares
Net buyer
$349.0K
Total sold
4
Open market trades
0B · 4S
5
Total transactions
14K acquired · 8.33K disposed
Non-Derivative Transactions5
Common Stock
Direct
Shares
+14K
Price / share
—
Trade value
—
% of position
12.6%
4/13/2026
111.23K→125.23K
Common Stock
Direct
Shares
−65.00
Price / share
$28.85
Trade value
$1.88K
% of position
0.1%
4/13/2026
125.23K→125.16K
Common Stock
Direct
Shares
−9.00
Price / share
$41.07
Trade value
$369.63
% of position
0.0%
4/14/2026
125.16K→125.15K
Common Stock
Direct
Shares
−7.24K
Price / share
$41.93
Trade value
$303.52K
% of position
5.8%
4/14/2026
125.15K→117.91K
Common Stock
Direct
Shares
−1.01K
Price / share
$42.61
Trade value
$43.21K
% of position
0.9%
4/15/2026
117.91K→116.90K
Total
Net shares
+5.67K
Net value
-$348.97K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock Direct | 4/13/2026 | A · Award | +14K | — | — | 12.6% | 111.23K | 125.23K |
| Common Stock Direct | 4/13/2026 | S · Sale | −65.00 | $28.85 | $1.88K | 0.1% | 125.23K | 125.16K |
| Common Stock Direct | 4/14/2026 | S · Sale | −9.00 | $41.07 | $369.63 | 0.0% | 125.16K | 125.15K |
| Common Stock Direct | 4/14/2026 | S · Sale | −7.24K | $41.93 | $303.52K | 5.8% | 125.15K | 117.91K |
| Common Stock Direct | 4/15/2026 | S · Sale | −1.01K | $42.61 | $43.21K | 0.9% | 117.91K | 116.90K |
| Total | +5.67K | -$348.97K | ||||||
Derivative Transactions0
No derivative transactions reported